<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02593331</url>
  </required_header>
  <id_info>
    <org_study_id>GC29819</org_study_id>
    <nct_id>NCT02593331</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance</brief_title>
  <official_title>A Phase Ia, Randomized, Blinded, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous BFKB8488A in Otherwise Healthy Overweight and Obese Volunteers With Likely Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability profile of BFKB8488A following
      subcutaneous (SC) administration in overweight and obese participants (body mass index [BMI]
      greater than [&gt;] 27 to less than or equal to [&lt;/=] 40 kilograms per square meter [kg/m^2])
      with markers of insulin resistance. Single ascending fixed doses of BFKB8488A will be
      evaluated. Participants will be randomized into 7 sequential ascending fixed-dose cohorts of
      BFKB8488A SC or placebo and safety reviews will be performed before escalation to higher dose
      cohorts. Additionally, following the ascending fixed-dose SC cohorts, a separate cohort will
      open to evaluate the PK of BFKB8488A after intravenous (IV) administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2015</start_date>
  <completion_date type="Actual">March 28, 2017</completion_date>
  <primary_completion_date type="Actual">March 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From baseline up to 20 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum BFKB8488A Concentration</measure>
    <time_frame>SC Cohort: predose (Hour 0), 4, 24, 72 hours post Day 1 dose, Days 6, 8, 11, 15, 22, 29, 36, 43, 57, 85, 113; IV Cohort: end of infusion on Day 1, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72 hours post Day 1 dose, Days 6, 8, 15, 22, 29, 36, 43</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching to BFKB8488A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BFKB8488A SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single ascending SC dose of BFKB8488A in each dose escalation cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BFKB8488A IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single IV dose of BFKB8488A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BFKB8488A</intervention_name>
    <description>Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.</description>
    <arm_group_label>BFKB8488A SC</arm_group_label>
    <arm_group_label>BFKB8488A IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive a single dose of placebo on Day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with BMI &gt;/=30 kg/m^2 and &lt;/=40 kg/m^2 or BMI &gt;27 kg/m^2 and &lt;30 kg/m^2
             and Homeostatic Model Assessmentâˆ’Insulin Resistance (HOMA-IR) &gt;3.60 or waist
             circumference &gt;100 centimeters (cm) (males) or 88 cm (females) or fasting plasma
             insulin &gt;/=15 milli international unit per liter (mIU/L) or fasting plasma glucose
             &gt;/=100 milligrams per deciliter (mg/dL) and &lt;126 mg/dL or hemoglobin A1c (HbA1c) &gt;5.6
             percent (%) and &lt;6.5%

          -  Negative pregnancy test

        Exclusion Criteria:

          -  A diagnosis of Type 2 diabetes mellitus at any time

          -  Pregnant, lactating or intending to become pregnant during the study or within 3
             months after the study dose is administered

          -  Uncontrolled intercurrent illness or any psychiatric illness

          -  Participants actively involved in a weight loss or dietary program within the last 6
             months

          -  History of surgical procedures for weight loss

          -  History of eating disorder

          -  Uncontrolled hypertension (systolic &gt;/=140 millimeter of mercury [mmHg] or diastolic
             blood pressure &gt;/=90 mmHg) either on or off therapy at screening or Day -2

          -  Fasting triglycerides &gt;500 mg/dL (5.64 millimoles per liter [mmol/L]) or low density
             lipoprotein (LDL) &gt;160 mg/dL (4.14 mmol/L) at screening

          -  Any serious medical condition or abnormality in clinical laboratory tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2015</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

